Literature DB >> 3510612

Betaxolol vs timolol. A six-month double-blind comparison.

R H Stewart, R L Kimbrough, R L Ward.   

Abstract

Betaxolol hydrochloride (0.5%) and timolol maleate (0.5%) were compared in a six-month randomized, double-blind study involving 29 patients with glaucoma. The two drugs were comparable with regard to efficacy in lowering intraocular pressure. Betaxolol effected an average reduction of 7.6 mm Hg (26%); timolol, 8.4 mm Hg (29%). No patient required adjunctive medications during this study. Ocular side effects were mild and similar for both treatments. Neither drug affected corneal sensitivity, visual acuity, basal tear production, or pupil size. Since betaxolol has been shown to have little effect on the cardiopulmonary system, it should be strongly considered for the treatment of glaucoma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3510612     DOI: 10.1001/archopht.1986.01050130056019

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  12 in total

Review 1.  Should beta blockers be abandoned as initial monotherapy in chronic open angle glaucoma? The controversy.

Authors:  I Goldberg
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

Review 2.  Glaucoma management: relative value and place in therapy of available drug treatments.

Authors:  Deepak Sambhara; Ahmad A Aref
Journal:  Ther Adv Chronic Dis       Date:  2014-01       Impact factor: 5.091

Review 3.  Pharmacological therapy for glaucoma: a review.

Authors:  P F Hoyng; L M van Beek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 4.  Topical drug therapy in glaucoma.

Authors:  Hemma Resch; Gerhard Garhofer
Journal:  Wien Med Wochenschr       Date:  2006-09

5.  Effects of Brimonidine and Timolol on the Progression of Visual Field Defects in Open-angle Glaucoma: A Single-center Randomized Trial.

Authors:  Yu Yokoyama; Ryo Kawasaki; Hidetoshi Takahashi; Shigeto Maekawa; Satoru Tsuda; Kazuko Omodaka; Toru Nakazawa
Journal:  J Glaucoma       Date:  2019-07       Impact factor: 2.503

6.  A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma.

Authors:  P G Watson; M F Barnett; V Parker; J Haybittle
Journal:  Br J Ophthalmol       Date:  2001-08       Impact factor: 4.638

Review 7.  Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.

Authors:  M M Buckley; K L Goa; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

8.  Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of action.

Authors:  Matt H Oltmanns; Sandeep S Samudre; Ivan G Castillo; Alireza Hosseini; Aron H Lichtman; Robert C Allen; Frank A Lattanzio; Patricia B Williams
Journal:  J Ocul Pharmacol Ther       Date:  2008-02       Impact factor: 2.671

Review 9.  Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.

Authors:  A M Brooks; W E Gillies
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

10.  Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension.

Authors:  Luciano Quaranta; Raffaele Turano; Teodoro Pizzolante
Journal:  Clin Ophthalmol       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.